Strides Pharma Science may resume Ranitidine drug sale in US market

Amid an ongoing controversy around popular drug Ranitidine, pharma major Strides Pharma Science could soon resume sale of the antacid in the US market as the country’s drug regulator has found them safe for use. The company holds 33 per cent share in the US Ranitidine prescription market.

According to the US Food and Drug Administration (USFDA), Strides’ Ranitidine tablets 300 mg is within the acceptable limits for N-nitrosodimethylamine (NDMA) of 96 nanograms per day or 0.32 ppm.

“We will soon provide updates on potential recommencement of product distribution in US markets of Ranitidine based on available test results,” said the company.

The